Fig. 3
From: A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic
a PBMC proliferation assay analysis by Alamar Blue reduction. Starved ConA-activated PBMCs were stimulated with different equimolar concentrations (1–105 pM) of VGRmIL2-IC or mIL-2 for 48 h. b IFN-γ secretion analysis by ELISA assay. PBMCs were stimulated with 30 pmol of VGRmIL2-IC or mIL-2. After 48 h of incubation, the supernatants were collected, and the secreted IFN-γ levels were measured. The results are the mean ± SD values of triplicate experiments. Data analysis was performed using a one-way ANOVA test (ns: not significant; ****P < 0.0001)